Vilobelimab is a monoclonal antibody commercialized by InflaRx, with a leading Phase II program in Cardiovascular Inflammation. According to Globaldata, it is involved in 12 clinical trials, of which 9 were completed, 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vilobelimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Vilobelimab is expected to reach an annual total of $83 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Vilobelimab Overview

Vilobelimab (IFX-1) is under development for the treatment of advanced or metastatic cutaneous squamous cell carcinoma (cSCC), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), anti-neutrophil cytoplasmic antibody-associated vasculitis, septic organ dysfunction, hidradenitis suppurativa, systemic inflammatory response syndrome (SIRS) induced organ dysfunction (sepsis, septic shock, inflammation, multiple organ dysfunction), acute lung injury, pyoderma gangraenosum, chronic inflammation, cancer and coronavirus disease 2019 (COVID-19). It is administered through intravenous route. The drug candidate is a humanized monoclonal antibody. It was under development for community-acquired pneumonia.

It was under development for anti-neutrophil cytoplasmic antibody-associated vasculitis and hidradenitis suppurativa.

InflaRx Overview

InflaRx is a clinical-stage bio pharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers the development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications. Its pipeline products includes IFX-1 and IFX-2. InflaRx operates in various research and development programs in life science sectors. The company offers antibodies that are able to fulfil requirements determined by InflaRx for generation of suitable drug candidates. It offers research services through collaboration with universities and biotech companies. InflaRx is headquartered in Jena, Germany.

The operating loss of the company was EUR47.6 million in FY2021, compared to an operating loss of EUR33.9 million in FY2020. The net loss of the company was EUR45.6 million in FY2021, compared to a net loss of EUR34 million in FY2020.

For a complete picture of Vilobelimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.